A novel stimulator device to treat gait deficits in multiple sclerosis (MS) patients with mild to moderate symptoms earned a nod from the FDA Friday. The device, known as the Portable Neuromodulation ...

NEWTOWN, Pa., March 09, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (HSDT) (“Helius”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance ...

--PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people with Multiple Sclerosis-- --Statistically ...

Could a new device called a portable neuromodulation stimulator (PoNS) help improve your mobility and balance with multiple sclerosis? PoNS is a device that delivers mild electrical pulses to two ...

The US Food and Drug Administration (FDA) has approved the Portable Neuromodulation Stimulator (PoNS, Helius Medical Inc) for the short-term treatment of walking impairments as a result of mild to ...

Company’s First-Ever ANPT Booth Sponsorship Enables Specialists to Learn More about this Breakthrough Technology on Eve of National Physical Therapy Month Helius’ debut at the conference is timely, ...

Please provide your email address to receive an email when new articles are posted on . The FDA has authorized the marketing of a neuromuscular tongue stimulator to improve short-term gait deficit in ...

NEWTOWN, Pa. - Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company with a market capitalization of $3.84 million, announced significant findings from the PoNS Therapeutic Experience ...

The FDA authorized marketing of the Portable Neuromodulation Stimulator (Pons) for short-term treatment of gait issues arising from mild to moderate symptoms associated with multiple sclerosis (MS) ...

NEWTOWN, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) is expanding its presence at the 2024 American Physical Therapy Association (APTA) Combined Sections ...